Form 4: REGENXBIO Director Jean Bennett Reports Significant Equity Awards

REGENXBIO Inc. Director Jean Bennett has reported the acquisition of 7,768 restricted stock units and 39,815 stock options, reflecting new equity compensation.

Summary

• Jean Bennett, a Director of REGENXBIO Inc. (RGNX), reported the acquisition of equity securities on May 30, 2025.
• The acquisition includes 7,768 shares of common stock underlying a time-based restricted stock unit (RSU) award, granted at a price of $0.00.
• These RSU shares will vest 100% on May 1, 2026, contingent upon Ms. Bennett's continuous service to the Issuer.
• Additionally, Ms. Bennett acquired 39,815 stock options with an exercise price of $8.85 per share, also granted at a price of $0.00.
• These stock options will vest in 12 equal monthly installments starting from May 30, 2025, subject to her continuous service.
• The stock options have an expiration date of May 30, 2035.
• Following these transactions, Ms. Bennett beneficially owns 19,054 shares of common stock and 39,815 stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates increased alignment between a director's interests and shareholder value through equity compensation, which is a standard and generally well-regarded practice.

Positives

• The acquisition of restricted stock units and stock options by a director aligns their interests more closely with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining experienced board members in the biotechnology sector.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook, focusing solely on insider equity transactions.

Industry Context

Equity compensation, including restricted stock units and stock options, is a prevalent and standard component of executive and director compensation packages across the biotechnology and pharmaceutical industries. This practice is designed to align the interests of company leadership with long-term shareholder value creation, particularly in sectors with long development cycles and significant R&D investments like gene therapy.

Comparison to Industry Standards

• The structure of equity compensation, involving both RSUs and stock options with vesting schedules tied to continuous service, is consistent with typical compensation practices for non-employee directors in publicly traded biotechnology companies.
• The grant of options at an exercise price of $8.85 and RSUs at $0.00 is standard for incentive-based compensation, reflecting the market value at grant for options and the inherent value of shares for RSUs.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with long-term shareholder value, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• The 7,768 restricted stock units are scheduled to vest on May 1, 2026.
• The 39,815 stock options will continue to vest in 12 equal monthly installments following May 30, 2025.

Key Dates

Keywords

REGENXBIO, RGNX, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Biotechnology, Gene Therapy